None listed
Conditions
Interventions
None listed
Sponsors
Dongwha Pharmaceutical
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? All patients diagnosed with essential (primary) hypertension as major or sub disease whose first diagnosis date was recorded from January 1, 2014 to December 31, 2018. ? Patients with heart failure, sleep apnea, menopause, obesity, dyslipidemia, type 2 diabetes before or after diagnosis of hypertension ? Patients with prescription record of ARB+CCB or ARB+HCTZ-based combinations ? Patients with a record of at least 4 weeks of prescription for the combinations and with confirmed daily dose ? Patients who underwent BP measurement within +/- 7 days of the prescription date based on the start and end of prescription of the combinations
Exclusion criteria
Exclusion criteria: Patients who do not meet the inclusion criteria are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A change in blood pressure measured from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure response rate (DBP; < 90mmHg or reduction of = 10mmHg, SBP; < 140mmHg or reduction of = 20mmHg);Goal rate (Combined SBP/DBP <140/90 mmHg and <130/80 mmHg in patients with diabetes mellitus and renal disease, respectively);Changes in metabolic risk (e.g. glucose, HbA1c, TC, LDL-C, HDL-C, TG);new onset of metabolic syndrome, including diabetes (NODM) | — |
Countries
Korea, Republic of
Contacts
Public ContactHeesang Eum
Yonsei University Health System, Severance Hospital
Outcome results
None listed